@article{17ef5b7d1b20472590a7810edb28d10c,
title = "Novel Treatment Paradigms in Acute Myeloid Leukemia",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous disease marked by the presence of several driver mutations and molecular subgroups even in a single patient. The genetic and molecular heterogeneity is also reflected by a progressive shift from a morphologic classification to one informed by causative genomic changes. Cytogenetic results and somatic mutations are increasingly being utilized to guide use of intensive chemotherapy and low-intensity chemotherapy, particularly among older adults. Utilization of next-generation sequencing in AML has led to increasing use of targeted treatments for actionable mutations. Quantitative real-time polymerase chain reaction-based mutational analysis and multicolor flow cytometry offer sensitive assays that can detect minimal residual disease (MRD). Several studies have shown that MRD negativity, as defined by specified cutoff values, is highly prognostic with potential therapeutic implications. The last 3 years mark an unprecedented history in the drug development in AML with approval of 8 new drugs and large portfolio of ongoing early and late-phase trials of several promising drugs. Multiple combinatorial trials of approved agents and approval of newer agents in the future will continue to change the therapeutic landscape of AML.",
author = "Nabin Khanal and {Upadhyay Banskota}, Shristi and Bhatt, {Vijaya Raj}",
note = "Funding Information: V.R.B. reports receiving consulting fees from Takeda, Omeros, Agios, Abbvie, Partner therapeutics, Rigel pharmaceuticals and Incyte, and research funding (Institutional) from Abbvie, Pfizer, Jazz, Incyte, Tolero Pharmaceuticals, Inc., and National Marrow Donor Program. Drug support for a trial is provided by Oncoceutics. All other authors declared no competing interests for this work. Funding Information: This work was supported by the National Institute of General Medical Sciences, 1 U54 GM115458, which funds the Great Plains Institutional Development Award (IDeA) Clinical Translational Research (CTR) Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). Funding Information: This work was supported by the National Institute of General Medical Sciences, 1 U54 GM115458, which funds the Great Plains Institutional Development Award (IDeA) Clinical Translational Research (CTR) Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). Publisher Copyright: {\textcopyright} 2020 The Authors Clinical Pharmacology & Therapeutics {\textcopyright} 2020 American Society for Clinical Pharmacology and Therapeutics",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/cpt.1962",
language = "English (US)",
volume = "108",
pages = "506--514",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",
}